CHMP recommends Edurant for HIV-1 infection

The CHMP has adopted a positive opinion recommending the approval of Edurant (rilpivirine), a 25 mg tablet from Tibotec Pharma, as a once-daily treatment in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-na�ve adult patients with a viral load = 100,000 HIV-1 RNA copies/mL. Edurant is a non-nucleoside reverse transcriptase inhibitor. The drug was approved in the USA on 20 May 2011. The decisions were base on the ECHO and THRIVE trials which were published in 20 July 2011 The Lancet. see The Lancet, Vol. 378 No. 9787 pp 229-237 and Vol. 378 No. 9787 pp 238-246